


Imodium

TRADEMARK

(loperamide hydrochloride)

**symbol of
accuracy
in acute diarrhoea**



Imodium's specific action controls diarrhoea, relieving pain and abdominal cramps rapidly and effectively.

A tailored dosage regime means that patients only take Imodium when they really need it, minimising the risk of constipation and encouraging economy of medication. Patients will find Imodium capsules easy to take and the blister pack of just twelve capsules is convenient to carry throughout the working day.

Imodium

Simply Stops Diarrhoea-fast

**2 // stat and 1 /
at each loose stool**

Further information is available from :



JANSSEN PHARMACEUTICA
2340 Beerse, Belgium

or

JANSSEN PHARMACEUTICAL LTD.
Marlow, Bucks. SL7 1ET.

Presentation :

Hard gelatin capsules containing 2 mg loperamide hydrochloride and syrup containing 1 mg loperamide hydrochloride per 5 ml.

Indications :

Imodium* is indicated for the symptomatic control of acute diarrhoea of any aetiology.

Contra-indications and warnings etc. :

There are no specific contra-indications to Imodium*. Studies in animals have shown to abnormal teratogenic effects, however the use of loperamide during pregnancy is subject to the usual precautions. In trials, no side effects have been reported that can reliably be distinguished from the symptoms of the gastro-intestinal disorder being treated. As persistent diarrhoea can be an indicator of potentially more serious conditions, Imodium* should not be used for prolonged periods until the underlying cause of the diarrhoea has been investigated.

Dosage and Administration :

Acute Diarrhoea . Adults : Two capsules initially, followed by one capsule after every loose stool. The usual dosage is 3 to 4 capsules a day, the maximum daily dose should not exceed 8 capsules. **Children :** 4 to 8 years : Syrup 5 ml four times daily until diarrhoea is controlled. In children under 8 years, further investigation may be necessary if diarrhoea has not responded to three days' treatment. 9 to 12 years : Syrup 10 ml (or 1 capsule) four times daily until diarrhoea is controlled.

Basic NHS Cost :

12 capsules (ex 250 pack) 104p. (correct at time of printing)

Product Licence Numbers :

Capsules 0242/0028 - Syrup 0242/0040

BLADDER STONES REMOVED WITHOUT SURGERY



with complete safety, no trauma and high efficiency, with minimum waste of time.

CYSTOLITHS OF ANY SIZE AND DENSITY ARE DISINTEGRATED IN THE BLADDER BY

"URAT-1"

ELECTRO-HYDRAULIC LITHOTRIPTOR

successfully used with bladders of small volume, with neurogenic bladders and recurrent cystoliths.



THIS NEW TECHNIQUE OF CRUSHING BLADDER STONES FULLY REPLACES TRAUMATIC MECHANICAL LITHOTRIPSY AND SIGNIFICANTLY REDUCES SURGERY.



Supplier:

MEDEXPORT

Korp. 2, 31, Kakhovka U1. Moscow 113461, USSR. Telephone 121-01-54. Telex 7247.

Private Medical & Surgical Rehabilitation

The Rehabilitation Unit at Unsted Park provides facilities for the intensive rehabilitation of patients of all ages. Treatment is carried out by a highly qualified, multi-disciplinary team under medical supervision, comprising physiotherapists, remedial gymnasts, occupational therapists, art therapist, speech therapist and nurses. The team is responsible for regular assessments of patients and for establishing individual treatment programmes.

Subscribers to the main Private Contributory Schemes may claim benefits within the terms of these schemes.

Further information is available from the Matron,

Unsted Park

Munstead Heath, Godalming, Surrey.
Telephone: Bramley (048647) 2061.



PARDALE FOR PAIN RELIEF
PARDALE FOR PAIN RELIEF
PARDALE FOR PAIN RELIEF
PARDALE FOR PAIN RELIEF
PARDALE FOR PAIN RELIEF

Paracetamol 400mg Codeine Phosphate 9mg
Caffeine Hydrate 10mg

Full product information available on request



Dales Pharmaceuticals Limited

Barrows Lane, Steeton, Keighley, Yorkshire BD20 6PP
(Steeton 53222)

PL 0123 5015

ADVERTISEMENTS

PHARMACEUTICAL PRODUCTS

Readers are reminded that prescribers literature and clinical information are always available from advertisers on request.

New facilities at

ST. ANDREW'S HOSPITAL, NORTHAMPTON

THE KEMSLEY UNIT FOR TREATMENT OF BEHAVIOUR DISORDERS IN THE BRAIN-INJURED

Brain injuries, particularly when they result from severe diffuse trauma, as in road accidents, lead very often to both physical and behavioural disabilities.

The aim of the Kemsley Unit is to treat behaviour disorders whilst also providing physical rehabilitation—so bringing both areas of disability under sufficient control that the patient can progress to wider rehabilitation settings elsewhere or return to the community.

In this unit a Consultant Neuropsychiatrist heads a team of psychological, remedial and nursing staff who are specially trained in behavioural techniques.

EATING DISORDERS UNIT

St. Andrew's Hospital's range of specialised treatment facilities now includes specific nursing, medical and rehabilitative programmes for patients with eating disorders. The majority of patients will have anorexia nervosa type difficulties.

Treatment orientation is psychotherapeutic, although initial firm control over eating behaviour and realignment of body weight will be necessary.

This Unit is part of the admission area and is run by staff with specialist training.

Further information is available from the

Medical Director · St. Andrew's Hospital · Northampton NN1 5DG
Telephone Northampton (0604) 21311

**JUST PUBLISHED by
THE COLOUR ATLAS SPECIALISTS**



A Colour Atlas of Peripheral Vascular Diseases

William F. Walker DSc, ChM, FRCS(Ed), FRCS(Eng), FRS(Ed)
Consultant Surgeon, Ninewells Hospital, Dundee and
Reader in Surgery at University of Dundee, Scotland

An effective visual and textual aid to the diagnosis of one of the commonest causes of death in the Western world – vascular disease – is provided by the **241 colour and 76 black and white photographs** presented here

PAGES 112 SIZE 101/4in x 75/8in ISBN 0 7234 0738 X

On sale through good booksellers – price £15 – or, in case of difficulty, available from

WOLFE MEDICAL PUBLICATIONS
Wolfe House 3 Conway Street London W1P 6HE

Journal of medical ethics

A multi-disciplinary commentary on clinical practice published quarterly by the Society for the Study of Medical Ethics: London.

Papers appearing in Volume 5, 1979, include:

Deciding the care of severely malformed or dying infants (A. G. M. Campbell and R. S. Duff, Department of Child Health, Aberdeen and Department of Pediatrics, Yale University respectively); **The donation and transplantation of kidneys: should the law be changed?** (Ian Kennedy, King's College, University of London); **The thin red line** (Case conference discussion); **The teaching of medical ethics in the Federal Republic of Germany** (Eduard Seidler, Institute for the History of Medicine, University of Freiburg); A series of papers from the LMG annual conference on **Violence** (H. J. Eysenck, Claire and W. M. S. Russell, Jan Pahl, Sylvia Winterbottom, D. J. West and Conor Cruise O'Brien); **The incentive argument for the unionisation of medical workers** (Terrance C. McConnell, Department of Philosophy, University of North Carolina at Greensboro); **Statistical lives and the principle of maximum benefit** (Albert Weale, Department of Politics, University of York).

The teaching of medical ethics is also covered in a series of contributions from different countries.

Please send manuscripts for publication to:

Dr. A. V. Campbell, Editor, **Journal of medical ethics**, University of Edinburgh, New College, The Mound, Edinburgh EH1 2LX, Scotland.

*Annual Subscription: Inland £16.00;
Overseas US\$40.00*

ORDER FROM: Professional & Scientific Publications,
Tavistock House East, Tavistock Square, London
WC1H 9JR or through any leading subscription agent.

NATRILIX®

indapamide

a primary antihypertensive agent

Natrilix offers a simple, effective means of controlling blood pressure both in newly diagnosed and in poorly controlled patients with mild to moderate hypertension

Prescribing information

Presentation

Pink biconvex sugar-coated tablets each containing 2.5 mg indapamide hemihydrate.

Uses

For the treatment of hypertension.

Dosage and administration

Adults


The dosage is one tablet daily to be taken in the morning.

Children

There is no experience of the use of this drug in children.

Contra-indications, warning, etc.

There are no absolute contra-indications to the use of Natrilix but caution should be exercised when prescribing it in cases of severe renal or hepatic impairment. As with all new drugs, the administration of Natrilix should be avoided during pregnancy although no teratological effects have been seen in animals. At doses higher than that recommended, Natrilix has a diuretic effect, therefore it is not recommended to prescribe it with a diuretic agent which may cause hypokalaemia. Also, slight weight loss has been reported in some patients taking Natrilix. Reported side effects have included nausea and headache,



but they are generally uncommon and mild in nature.

Serum urate levels may rise slightly but there is no evidence that glucose tolerance is adversely affected.

Box of 30 tablets.

Product licence number 0093/0022.

NATRILIX is available as:
FLUDEX® in Africa, Belgium, France, Holland, Portugal, Switzerland.
NATRILIX® in English speaking Countries of Africa, Brazil, Central America, Germany, Ireland, Italy, Middle East, South East Asia, United Kingdom.
TERTENSIF® in Spain.
NATRIX® in Korea.

Further information is available on request from
Servier Laboratories Ltd.,
Servier House, Horsenden Lane
South, Greenford, Middx.
UB6 7PW.



Les Laboratoires Servier,
22, rue Garnier - 92201 Neuilly -
France.

one tablet daily

WHY NOT SUBSCRIBE TO THE SPECIALIST JOURNALS PUBLISHED BY THE BMA:—A SELECTION INCLUDES

British Journal of Family Planning, Cardiovascular Research, Annals of the Royal College of Surgeons, Annals of Clinical Biochemistry.

FULL DETAILS OF SUBSCRIPTION RATES FROM BMA SPECIALIST PUBLICATIONS: BMA HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR
TELEPHONE 01-387 4499 EXT. 309.

New strength tablet from Geigy



VOLTAROL[®] 50

diclofenac sodium

bridges the gap
between efficacy and tolerability

Rheumatoid arthritis

Osteoarthritis

Simpler dosage for better patient compliance

Mode of action Voltarol is a non-steroidal agent with marked analgesic/anti-inflammatory and antipyretic properties. Like most other drugs in this class, it is an inhibitor of prostaglandin synthetase.

Indications Rheumatoid arthritis, osteoarthritis.

Dosage Severe cases: 1 x 50 mg tablet 3 times daily. Maintenance therapy: 1 x 50 mg tablet morning and evening may be sufficient.

Mild cases: Initially 1 x 25 mg tablet 3 times daily. Maintenance dosage should be adjusted to the minimum amount that will provide continuous therapeutic control.

Contraindications Peptic ulcer. Voltarol is contra-indicated in asthmatic patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory agents with prostaglandin synthetase inhibiting activity.

Precautions Voltarol should not be prescribed during pregnancy, unless there are compelling reasons for doing so. Patients with a history of peptic ulcer, haematemesis or melaena, or with severe hepatic or renal insufficiency, should be kept under close surveillance. Voltarol has been reported to depress salicylate levels and vice versa; the clinical relevance of this phenomenon is not yet known.

Warnings and side-effects Initially, some patients may complain of epigastric pain, nausea and diarrhoea, headache and slight dizziness. These side-effects are often transient, disappearing with continuation of medication. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminases have been reported. Very rarely peptic ulcer and haematemesis or melaena have been reported, mainly in patients with a history of such disorders, or who were receiving concomitant antirheumatic medication.

Accidental overdosage There is no known antidote to Voltarol and the treatment is symptomatic. Immediate treatment

consists of forced emesis to recover undigested tablets.

Pharmaceutical precautions Storage - protect from moisture.

Legal category Prescription only.

Presentation Voltarol, sodium-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate, is available as: yellow, round, slightly bi-convex, enteric coated tablets with bevelled edges, approximately 7 mm diameter, imprinted GEIGY on one side. Each tablet contains 25 mg. Voltarol is also available as: light-brown, round, slightly bi-convex, enteric coated tablets with bevelled edges, approximately 8 mm diameter, imprinted GEIGY. Each

tablet contains 50 mg.

Package quantities
Voltarol 25 mg Packs of 100.
Basic N.H.S. price £9.00.
Voltarol 50 mg Packs of 100.
Basic N.H.S. price £17.50.

Further information Pharmacodynamic studies have shown no potentiation of oral hypoglycaemic and anticoagulant drugs.

Product licence numbers
Tablets 25 mg, PL0001/0036.
Tablets 50 mg, PL0001/0082.

Product licence holder
Geigy Pharmaceuticals, Horsham, West Sussex.